Loading...
•
Jun 30, 2024
Zura Bio Q2 2024 Earnings Report
Zura Bio reported its second quarter 2024 financial results.
Key Takeaways
Zura Bio reported a net loss of $12.7 million for the second quarter of 2024. The company's cash and cash equivalents were $188.4 million as of June 30, 2024, expected to support operations through 2027. The company is advancing its Phase 2 clinical programs in SSc and HS.
Cash and cash equivalents were $188.4 million as of June 30, 2024.
R&D expenses were $5.5 million for the second quarter of 2024.
G&A expenses were $6.2 million for the first quarter of 2024.
Net loss for the second quarter of 2024 was $12.7 million or $0.17 per share.
Zura Bio
Zura Bio
Forward Guidance
Zura Bio anticipates that its existing cash and cash equivalents and investments should be sufficient to support operations as currently planned through 2027.